Alexei A. Podtelezhnikov

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index3.7kcitations50works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Structure and Dynamics(8), Mitochondrial Function and Pathology(7), Computational Drug Discovery Methods(6), Alzheimer's disease research and treatments(5), Pharmacogenetics and Drug Metabolism(5)

Publications50 total

A mechanistic biomarker investigation of fialuridine hepatotoxicity using the chimeric TK-NOG Hu-liver mouse model and in vitro micropatterned hepatocyte cocultures
Toxicology Research·2024· 2 citedOpen Access
A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies
Toxicological Sciences·2022· 19 citedOpen Access
Understanding the effect of increased cell specific productivity on galactosylation of monoclonal antibodies produced using Chinese hamster ovary cells
Journal of Biotechnology·2021· 22 cited
Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline
Toxicological Sciences·2020· 27 cited
Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury
Toxicological Sciences·2020· 31 citedOpen Access
Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Scientific Reports·2020Open Access
Quantitative Transcriptional Biomarkers of Xenobiotic Receptor Activation in Rat Liver for the Early Assessment of Drug Safety Liabilities
Toxicological Sciences·2020· 42 citedOpen Access
AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated With Tumorigenic Risks in Rats
Toxicological Sciences·2019· 17 cited
Transcriptomic biomarkers to assess the liver and metabolic responses associated with bioactivation mechanisms of drug induced liver injury
Drug Metabolism and Pharmacokinetics·2019· 1 cited
Qualification and application of an in vitro liver model early in pharmaceutical development to help derisk drug-induced liver injury (DILI)
Drug Metabolism and Pharmacokinetics·2019· 1 cited
Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
Fluids and Barriers of the CNS·2018· 108 citedOpen Access
MOESM1 of Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
Figshare·2018Open Access
MOESM3 of Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
Figshare·2018Open Access
MOESM4 of Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
Figshare·2018Open Access
MOESM2 of Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
Figshare·2018Open Access
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Scientific Reports·2017· 66 citedOpen Access
Transcriptional Profiling of Cholinergic Neurons From Basal Forebrain Identifies Changes in Expression of Genes Between Sleep and Wake
SLEEP·2017· 20 citedOpen Access
Erratum to: Network-driven plasma proteomics expose molecular changes in the Alzheimer’s brain
Molecular Neurodegeneration·2016· 1 citedOpen Access
Network-driven plasma proteomics expose molecular changes in the Alzheimer’s brain
Molecular Neurodegeneration·2016· 37 citedOpen Access
Toxicogenomics in drug development: a match made in heaven?
Expert Opinion on Drug Metabolism & Toxicology·2016· 21 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Keith Q. Tanis(26), David J. Stone(13), Andrey Loboda(10), Eva M. Finney(9), Frank D. Sistare(9), David L. Wild(7), Edward G. Stopa(6), Miles C. Miller(6), Lisan Parker(6), Ajay Verma(6), Andrew Baird(6), John E. Donahue(6), Brian P. Eliceiri(6), Conrad E. Johanson(6), Elena V. Nikonova(5), Tara Torabi(5), Amy G. Aslamkhan(5), Warren E. Glaab(5), Stephen Pacchione(5), James J Monroe(4)